Successful applicant companies from Israel will receive funding directly from the Israel Innovation Authority.

The Israel Innovation Authority will provide funding of up to 50% of the approved pilot validation expenses.

The Authority will provide an additional funding of 10% to companies located in the periphery of Israel (In addition to the budget approved for R&D costs).

Upon approval from both parties, Israeli companies will be entitled to 12 months of financial support, and will be eligible for a second year of funding subject to review of the project milestones.
The program will support collaboration projects for up to 24 months overall.

Funding awarded by the Israel Innovation Authority will be granted upon approval from both parties and shall comply with the Israeli laws and regulations for Industrial R&D.
For more information regarding Israeli laws and regulations, please refer to the Israel Innovation Authority’s Hebrew site.

Mayo Clinic may provide in kind services, expertise and/or use of facilities.  An appropriate agreement between successful applicant companies and Mayo will need to be entered into prior to project initiation.

In exchange for such services, expertise and/or use of facilities, Mayo Clinic and the Israeli companies may agree on equity investment by Mayo Clinic Ventures and/or a revenue share of the products or services that are the subject of the project.

Mayo Clinic may provide in-kind project resources as follows:

• Internal champion to co-develop and identify the parameters of the product/technology and potential use cases
• Test and validate the product given pre-identified parameters
• Deploy, roll-out and operationalize the product internally
• Assistance to co-commercialize the product, through introductions to partner health systems and entities
• Opportunity to interact with other companies and VC as appropriate